WASHINGTON, D.C. — Medicare patients could gain access to certain breakthrough medical devices months sooner under a new federal initiative designed to speed up approval and coverage decisions.
What This Means for You
- Some new medical devices may become available to Medicare patients faster
- Federal agencies will coordinate earlier to reduce approval delays
- Coverage decisions could happen in months instead of a year or more
The Centers for Medicare & Medicaid Services and the Food and Drug Administration last week announced a new “RAPID coverage pathway,” a program intended to streamline how certain medical devices are reviewed and approved for Medicare coverage.
The pathway focuses on Breakthrough Devices — a designation for technologies that treat serious conditions and address unmet medical needs — and aims to shorten the gap between FDA approval and Medicare coverage.
How the New Pathway Works
Under the current system, even after the FDA approves a medical device for use, Medicare coverage decisions can take a year or longer, delaying patient access.
The RAPID pathway allows the FDA and CMS to coordinate earlier in the development process so that the same clinical evidence — data showing whether a device works and is safe — can be used for both regulatory approval and Medicare coverage decisions.
This alignment is intended to reduce duplication and speed up the process.
“FDA and CMS each play a critical role in getting new medical devices to patients, and they work most effectively when aligned sooner in that process,” CMS Administrator Dr. Mehmet Oz said.
Earlier Input on What Matters
As part of the program, CMS will work directly with device manufacturers earlier in development to identify which health outcomes are most relevant for Medicare patients.
To qualify, devices must be part of an Investigational Device Exemption study — a clinical trial that allows a device to be tested in humans before full approval — and include Medicare beneficiaries in the research.
The pathway applies to certain moderate- and high-risk devices, known as Class II and Class III devices, that meet the FDA’s Breakthrough criteria.
Faster Coverage Decisions
The new process is designed to create a more predictable timeline.
Under the RAPID pathway, CMS will issue a proposed National Coverage Determination — a nationwide decision on whether Medicare will pay for a treatment — on the same day a qualifying device receives FDA authorization.
That triggers a required 30-day public comment period.
Officials said the full process could lead to Medicare coverage in as little as two months after FDA approval, compared to a year or more under the current system.
FDA Commissioner Marty Makary said the effort is aimed at reducing delays.
“The American people deserve timely access to meaningful treatments without red tape or high costs,” Makary said.
Impact on Existing Programs
CMS said it will continue to offer other pathways for covering medical technologies but will pause new entries into its Transitional Coverage for Emerging Technologies program while it focuses on implementing the RAPID pathway.
Officials said lessons from the new program could be applied to improve other coverage processes.
What Happens Next
A formal proposal outlining the RAPID pathway will be published in the Federal Register, opening a 60-day public comment period.
CMS will review feedback before issuing a final notice, which will determine when the new pathway takes effect.
Officials said the initiative is part of a broader effort to improve access to innovative treatments while maintaining safety and oversight.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.